NasdaqGM:CRMDPharmaceuticals
CorMedix (CRMD): Assessing Valuation After Strong Profit Turnaround and Upbeat Revenue Guidance
CorMedix (CRMD) just released quarterly results showing a dramatic swing to profitability and sharp revenue growth compared to last year. The company also shared a confident revenue outlook for the next quarter. Investors are paying close attention.
See our latest analysis for CorMedix.
After swinging to profitability and increasing revenue, CorMedix’s stock has picked up short-term momentum, with a 1-month share price return of nearly 6 percent and a robust year-to-date gain of 36.7 percent...